Personalized mRNA Vaccine Cuts Melanoma Recurrence or Death Risk by 42 Percent
Merck and Moderna’s personalized mRNA vaccine Intismeran Autogene, combined with the immunotherapy drug Pembrolizumab, reduced the risk of melanoma recurrence or death by 42 percent compared with Pembrolizumab alone. The Phase 3 INTerpath-001 trial involved 1,137 patients whose high-risk tumors had been completely removed by surgery and followed them for an average of 24.6 months.
At the end of follow-up, 82.2 percent of patients receiving the combination remained recurrence-free, versus 70 percent in the immunotherapy-only group. The vaccine also reduced the risk of melanoma spreading to other parts of the body by 38 percent. Reported side effects included fever, fatigue and pain at the injection site, while the overall safety profile was similar to that seen in earlier trials.
Each vaccine is made from a sample of the individual patient’s tumor. Researchers identify mutations that produce distinctive proteins, then select up to three molecular signatures that can train the immune system to recognize and attack cancer cells. The treatment is intended to prevent recurrence after surgery, not to stop melanoma from developing in the first place. It remains investigational and must still secure regulatory approval. Its success could support similar approaches for other tumors, although producing a bespoke vaccine for every patient presents substantial cost and logistical challenges.
Continue in the app — vote & join in ➔